Comment
doi: 10.1200/JCO.23.00664.
Epub 2023 Jun 2.
Consent in Pharmacogenetic Testing
Affiliations
- PMID: 37267582
- DOI: 10.1200/JCO.23.00664
Item in Clipboard
Comment
Consent in Pharmacogenetic Testing
J Clin Oncol.
.
No abstract available
Comment on
-
DPYD Testing: Time to Put Patient Safety First.J Clin Oncol. 2023 May 20;41(15):2701-2705. doi: 10.1200/JCO.22.02364. Epub 2023 Feb 23. J Clin Oncol. 2023. PMID: 36821823 Free PMC article. No abstract available.
Similar articles
-
A review of consent practices and perspectives for pharmacogenetic testing.Pharmacogenomics. 2016 Sep;17(14):1595-605. doi: 10.2217/pgs-2016-0039. Epub 2016 Aug 17. Pharmacogenomics. 2016. PMID: 27533720 Free PMC article. Review.
-
The PREPARE study: benefits of pharmacogenetic testing are unclear.Lancet. 2023 Jun 3;401(10391):1851. doi: 10.1016/S0140-6736(23)00855-3. Lancet. 2023. PMID: 37270237 No abstract available.
-
The PREPARE study: benefits of pharmacogenetic testing are unclear.Lancet. 2023 Jun 3;401(10391):1850. doi: 10.1016/S0140-6736(23)00853-X. Lancet. 2023. PMID: 37270236 No abstract available.
-
The PREPARE study: benefits of pharmacogenetic testing are unclear.Lancet. 2023 Jun 3;401(10391):1850-1851. doi: 10.1016/S0140-6736(23)00854-1. Lancet. 2023. PMID: 37270235 No abstract available.
-
Challenges and Opportunities in Implementing Pharmacogenetic Testing in Clinical Settings.Annu Rev Pharmacol Toxicol. 2021 Jan 6;61:65-84. doi: 10.1146/annurev-pharmtox-030920-025745. Epub 2020 Oct 2. Annu Rev Pharmacol Toxicol. 2021. PMID: 33006916 Review.
Cited by
-
Assessment of the current status of real-world pharmacogenomic testing: informed consent, patient education, and related practices.Front Pharmacol. 2024 Feb 8;15:1355412. doi: 10.3389/fphar.2024.1355412. eCollection 2024. Front Pharmacol. 2024. PMID: 38410134 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
